帝京大学医学部内科学講座 腫瘍内科では、毎週月曜日に、最新のがん医療、がん研究に関するトピックに関する抄読会を開催しています。
ご興味のある方はぜひご参加ください。
お問い合わせ
2022年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
4月4日 | 本田 | Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival? |
Ann Surg Oncol (2022) 29:1807–1814 |
4月11日 | 研修医 岩佐 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastrooesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial |
Lancet Oncol . 2022 Feb;23(2):234-247. |
4月18日 | 風張 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | Lancet Oncol. 2020 May ; 21(5): 671–684. |
4月25日 | 市川 | Effectiveness of PD-(L)1 inhibitors alone or in combination with platinumdoublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data |
Ann Oncol . 2022 May;33(5):511-521. |
5月23日 | 市川 | Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative |
J Clin Oncol . 2022 May 1;40(13):1414-1427. |
7月4日 | 風張 | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
JTO Clin Res Rep . 2020 Mar 4;1(2):100020 |
8月1日 | 本田 | Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis |
Lancet Oncol 2022 Published Online |
8月15日 | 石原 | Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials |
J Thorac Oncol . 2022 Jun;17(6):758-767. |
8月22日 | 研修医 星谷 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
N Engl J Med 2022;387:9-20. |
9月12日 | 風張 | Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies |
Autoimmun Rev . 2020 Dec;19(12):102687. |
10月24日 | 市川 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer |
N Engl J Med 2022;386:1973-85. |
11月7日 | 風張 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | N Engl J Med 2022;387:9-20. |
11月21日 | 本田 | The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study |
Front Immunol . 2022 Sep 9;13:975246 |
12月5日 | 市川 | Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) |
J Thorac Oncol . 2022 Dec;17(12):1404-1414. |
2月6日 | 研修医 佐藤 | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma | N Engl J Med 2022;387:2113-25. |
2020年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
7月20日 | 丹澤 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study |
J Clin Oncol 38:2369-2379. |
8月3日 | 春山 | Treatment Decisions for Advanced Non‑Squamous Non‑Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy |
Patient. 2019 Apr;12(2):223-233. |
8月24日 | 研修医1年 | 症例報告 | |
9月14日 | 落合 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan |
Lung Cancer 129 (2019) 55–62 |
10月5日 | 風張 | 内科地方会予演会 | |
10月19日 | 研修医1年 | ||
11月2日 | 市川 | 肺癌学会予演会 |
2019年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
4月1日 | オリエンテーション | ||
4月8日 | 本田 | Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study |
Lancet Oncol 2018; 19: 1579–89 |
4月15日 | 研修医1年①星野 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer |
N Engl J Med 2019;380:1226-34. |
4月22日 | 研修医1年②平田 | Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial |
|
5月13日 | 上松先生の講義 | EGFR-TKIの爪囲炎のケア | |
5月27日 | 太田 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised,open-label, controlled, phase 3 trial | Lancet 2019; 393: 1819–30 |
6月3日 | 坂本 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-quamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial |
Lancet Oncol 2019 Published Online May 20, 2019 |
6月10日 | 渡邊 | Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database |
JAMA. 2019;321(14):1391-1399. |
6月17日 | 田上 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | J Clin Oncol. 2019 Jun 2:JCO1900934 |
6月24日 | 研修医1年 風張 | Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2):a multicentre, open-label, randomised, non-comparative,phase 2 trial | Lancet Oncol 2019; 20: 239–53 |
7月1日 | 落合予演会 | ||
7月8日 | 市川 | ASCO報告 | |
7月29日 | 石原 | Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors | Journal of Thoracic Oncology Vol. 14 No. 7: 1244-1254 |
8月5日 | 丹澤 | ASCO報告 | |
8月26日 | 研修医1年中島 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568):Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | J Clin Oncol 37:992-1000. |
9月2日 | 春山 | Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial |
TheOncologist 2017;22:1–8 |
10月7日 | 落合 | Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial | Ann Oncol. 2019 Aug 27. |
10月21日 | 本田 | Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study |
J Clin Oncol 37:1558-1565. |
11月25日 | 研修医2年 青木 | Association between waist circumference and risk of colorectal neoplasia in normal-weight adults |
J Gastroenterol Hepatol. 2019 Jun 27. |
12月2日 | 太田 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled,open-label, phase 3 trial | Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6 |
12月23日 | 研修医1年 菅 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial |
Lancet Oncol. 2018 Nov;19(11):1437-1448. |
1月27日 | 市川 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial | Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6. |
2月3日 | 坂本 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
N Engl J Med 2018;379:2108-21. |
2月10日 | 渡邊 | Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer | Gastroenterology. 2019 Dec 19. pii: S0016-5085(19)41937-9 |
2018年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
4月2日 | オリエンテーション | ||
4月23日 | 研修医1年
(田代) |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial |
Annals of Oncology 29: 624–631, 2018 |
5月7日 | 臨床研究読み合わせ | ||
5月14日 | 市川 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial |
Lancet 2017; 389: 255–65 |
5月21日 | 本田 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | |
6月4日 | 太田 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer |
N Engl J Med 2018; 378:2078-2092 |
6月11日 | 深澤 | 予演会 | |
6月18日 | 坂本 | 予演会 | |
6月25日 | 研修医1年(村川) | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer |
published on April 16,2018, at NEJM DOI: 10.1056/NEJMoa1716078 |
7月2日 | |||
7月9日 | 太田・深澤 | 臨床腫瘍学会予演会 | |
7月30日 | 研修医2年(安田) | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. | Lancet, Vol: 392, Issue: 10142, Page: 123-133,2018. |
8月6日 | 渡邊 | Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study |
Lancet Oncol. 2018 Feb;19(2):150-151
|
8月13日 | 石原 | Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFRActivating Mutations |
J Clin Oncol2018; 36:2244-2250. |
8月20日 | 丹澤 | Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial |
Lancet Oncol 2018; 19: 660–71 |
8月27日 | 研修医1年(小山) | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC |
N Engl J Med 2018;378:2288-301. |
9月10日 | 春山 | Edoxaban for the Treatment of Cancer- Associated Venous Thromboembolism |
N Engl J Med 2018;378:615-24. |
10月1日 | 落合 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | N Engl J Med 2018;378:113-25. |
10月15日 | 本田 | Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial |
J Clin Oncol. 2018 Jun 20:JCO2018 |
10月22日 | 研修医1年(小野) | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC |
N Engl J Med. 2018 Sep 25. |
10月29日 | 研修医1年 | ||
11月5日 | 太田 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial |
Lancet Oncol 2017; 18: 1590–99 |
11月12日 | 予演会 | ||
11月19日 | 石原 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer |
J Clin Oncol. 2018 Aug 28 |
11月26日 | 研修医2年(鈴木) | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | N Engl J Med. 2018 Oct 21 |
12月3日 | 坂本 | Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | N Engl J Med 2018;379:2027-39. |
12月10日 | 研修医1年(寺島) | Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer |
N Engl J Med 2018;379:2040-51. |
12月17日 | 研修医1年(中川) | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
N Engl J Med 2018;379:2040-51. |
1月7日 | 春山 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer | N Engl J Med 2018;379:2220-9. |
1月21日 | 市川 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer |
J Clin Oncol 36:2872-2878. |
1月28日 | 研修医2年(石渡) | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study |
Lancet 2019; 393: 156–67 |
2月4日 | 渡邊 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer |
N Engl J Med 2018;379:2495-505 |
2月18日 | 研修医1年(計田) | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial |
Lancet Oncol 2017; 18: 1454–66 |
2月25日 | 研修医1年(服部) | Apixaban to Prevent Venous Thromboembolism in Patients with Cancer |
N Engl J Med. 2019 Feb 21;380(8):711-719. |
3月4日 | 予演会 | ||
3月11日 | 丹澤 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer |
N Engl J Med 2018;379:1926-36. |
2017年度 開催記録
日付 |
担当 |
論文タイトル |
掲載雑誌 |
4月3日 |
オリエンテーション |
||
4月17日 |
研修医(金城) |
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial |
Lancet Oncol. 2017 May;18(5):663-671. |
4月24日 |
研修医(林) |
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer |
N Engl J Med 2017;376:629-40. |
5月1日 |
太田(真) |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Lancet 2017; 389: 917–29 |
5月8日 |
坂本 |
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Na¨ıve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi- Institutional Analysis |
J Clin Oncol 35:1070-1077. |
5月15日 |
市川 |
Use of chemotherapy near the end of life: what factors matter? |
Ann Oncol. 2017 Apr 1;28(4):809-817. |
5月22日 |
渡邊 | Developing Canadian oncology education goals and objectives for medical students: a national modified Delphi study | CMAJ Open. 2016 Jul 14;4(3):E359-E364. |
5月29日 |
臼井 |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study |
Lancet Oncol. 2016 Nov;17(11):1497-1508 |
6月5日 |
石原 |
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy | J Clin Oncol. 2017 Mar;35(7):709-717 |
6月12日 |
丹澤 |
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | N Engl J Med. 2017 Jun 4. |
6月19日 |
深澤 |
予演会 | |
6月26日 |
研修医(鈴木) |
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial | J Clin Oncol. 2017 Apr 1;35(10):1078-1085. |
7月10日 |
市川 | 臨床腫瘍学会予演会 | |
7月24日 |
予演会 | ||
7月31日 |
本田 | Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review |
Cancer Treatment Reviews 53 (2017) 25–37 |
8月7日 |
春山 | A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS®) hydromorphone in opioid-naive cancer patients:Results of the Korean South West Oncology Group study | Pain Res Manag Vol 20 No 6 November/December 2015 |
8月14日 |
太田 | Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial | Lancet Oncol 2017; 18: 895–903 |
8月21日 |
研修医2年(落合) | Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer |
J Clin Oncol 35:1921-1928 |
8月28日 |
研修医1年(田村) |
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck |
N Engl J Med 2016;375:1856-67. |
9月4日 |
坂本 | First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cance | The Breast 35 (2017) 78e84 |
9月11日 |
渡邊 | Guideline-Based Statin Eligibility, Cancer Events, and NoncardiovascularMortality in the Framingham Heart Study | J Clin Oncol 35:2927-2933. |
9月25日 |
臼井 | ミニレクチャー | |
10月2日 |
石原 | 内科学会地方会予演会 | |
10月23日 |
丹澤 | Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer |
N Engl J Med 2017; 377:1919-1929 |
10月30日 |
研修医1年(森田) |
Statin Use After Diagnosis of Colon Cancer and Patient Survival | Gastroenterology 2017;153:470–479 |
11月6日 |
深澤 | 予演会 | |
11月13日 |
太田 | Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation |
Clinical Lung Cancer, Vol. 18, No. 6, 698-705 |
11月20日 |
本田 | Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind,placebo-controlled trial |
Lancet 2017; 390: 1833–42 |
11月27日 |
研修医2年(安川) | Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain |
J Clin Oncol 34:436-442. 2015 |
12月4日 |
市川 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer |
published on November18, 2017, at NEJM. |
12月11日 |
坂本 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) |
Annals of Oncology 28: 2698–2706, 2017 |
12月18日 |
春山 | Comparative clinical effects of hydromorphone and morphine: a meta-analysis |
British Journal of Anaesthesia 107 (3): 319–28 (2011) |
12月25日 |
研修医1年(佐山) |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet. 2017 Dec 2;390(10111):2461-2471. |
1月15日 |
渡邊 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials |
Lancet Oncol 2018; 19: 27–39 |
1月22日 |
臼井 | Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases |
Journal of Thoracic Oncology Vol. 12 No. 9: 1442-1445 |
1月29日 |
石原 | Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial |
Lancet Oncol 2017; 18: 1610–23 |
2月5日 |
丹澤 | HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/ Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma |
J Clin Oncol 36:359-366. |
2月19日 |
研修医2年(落合) | 予演会 | |
2月26日 |
研修医1年(友寄) | Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial |
J Clin Oncol. 2017 Dec 8:JCO2017749457. |
3月5日 |
春山 | Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy |
JAMA, April 3, 2013—Vol 309, No. 13 |
2016年度 開催記録
日付 |
担当 |
論文タイトル |
掲載雑誌 |
4月4日 |
オリエンテーション |
||
4月11日 |
夏目 |
Preferences of Advanced Cancer Patients for Communication on Anticancer Treatment Cessation and the Transition to Palliative Care |
|
4月18日 |
坂本 |
Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer |
|
4月25日 |
研修医1年 (三須) |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L |
|
5月2日 |
渡邊 |
Multicenter Cohort Study on the Survival Time of Cancer Patients Dying at Home or in a Hospital:Does Place Matter? |
|
5月9日 |
本田 |
救急勉強会① |
|
5月16日 |
救急勉強会② |
||
5月23日 |
市川 |
臨床試験 |
|
5月30日 |
深澤 |
A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile |
|
6月6日 |
夏目 |
Early administration of epinephrine (adrenaline) in patients with cardiac arrest with initial shockable rhythm in hospital: propensity score matched analysis |
|
6月13日 |
太田 |
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled,phase 3 study |
|
6月20日 |
研修医2年 (落合) |
PROCLAIM: Randomized Phase III Trial of Pemetrexed- Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer |
|
6月27日 |
研修医1年 (竹下) |
Pembrolizumab versus docetaxel for previously treated,PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial |
|
7月4日 |
坂本 |
EGFR‑TKI rechallenge with bevacizumab in EGFR‑mutant non‑small cell lung cancer |
|
7月11日 |
深澤 |
予演会 |
|
8月1日 |
臼井 |
||
8月8日 |
夏目 |
Impact of bevacizumab in combination with erlotinib on EGFR-mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification |
Int. J. Cancer: 138, 1024–1032 (2016) |
8月15日 |
研修医1年 (安川) |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting |
N Engl J Med 2016;375:134-42. |
8月22日 |
渡邊 |
Facilitation of Drug Transport across the Blood–Brain Barrier with Ultrasound and Microbubbles |
Pharmaceutics 2015, 7, 275-293 |
8月29日 |
医局会 |
||
9月12日 |
医局会 |
||
9月26日 |
本田 |
PROCLAIM: Randomized Phase III Trial of Pemetrexed- Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer |
J Clin Oncol 2016; 34:953-962. |
10月3日 |
太田 |
Combined chemotherapy with cisplatin, etoposide, andirinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial |
Lancet Oncol 2016; 17: 1147–57 |
10月17日 |
深澤 |
A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer Results of the Phase II Randomized ABIGAIL Study (BO21015) |
Journal of Thoracic Oncology 2014; 9(6):848-855 |
10月24日 |
研修医1年 (本田) |
Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs | J Thorac Oncol. 2016 April ; 11(4): 556–565. |
10月31日 |
研修医2年 (松本) |
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer |
N Engl J Med. 2016 Oct 8. [Epub ahead of print] |
11月7日 |
市川 |
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. | Lancet Oncol. 2016 Oct 24. pii: S1470-2045(16)30532-0 |
11月14日 |
坂本 |
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study | Lung Cancer. 2016 Nov;101:1-8. |
11月21日 |
深澤(予演会) |
||
11月28日 |
研修医2年 (大野) |
Ramucirumab versus placebo in combination with secondline FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after fi rst-line therapy with bevacizumab, oxaliplatin, and a fl uoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study |
Lancet Oncol 2015; 16: 499–508 |
12月5日 |
渡邊 | 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based,observational study | Lancet Oncol 2016; 17: 1203–16 |
12月12日 |
臼井 | United States Health Care Reform Progress to Date and Next Steps |
JAMA. 2016;316(5):525-532. |
12月26日 |
研修医1年 (磯崎) |
Association Between Palliative Care and Patient and Caregiver Outcomes A Systematic Review and Meta-analysis |
JAMA. 2016;316(20):2104-2114. |
1月23日 |
研修医2年 (豊田) |
予演会 | |
1月30日 |
研修医2年 (春山) |
予演会 | |
2月6日 |
石原 | Outcome in patients with small cell lung cancer re-irradiated for brainmetastases after prior prophylactic cranial irradiation | Lung Cancer 101 (2016) 76–81 |
2月13日 |
本田 | Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial | Lancet 2016; 388: 2004–14 |
2月20日 |
プロトコール読み合わせ | ||
2月27日 |
研修医1年 (水川) |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):an international, randomised, double-blind, phase 3 trial | Lancet 2016; 388: 2997–3005 |
3月6日 |
太田(修) | ||
3月13日 |
太田(真) | ||
3月27日 |
深澤 |
2015年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
4月6日 |
内科学会予演会 |
||
4月13日 |
呼吸器学会予演会 |
||
4月20日 |
本田 |
Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient |
|
4月27日 |
研修医1年 (曽根Dr) |
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung c ancer (CheckMate 063): |
|
5月11日 |
森 |
学位論文研究報告 |
|
5月18日 |
太田 |
Initial Therapy with FOLFOXIRI and |
|
5月25日 |
深澤 |
Bevacizumab Combined With Chemotherapy for Platinum- |
|
6月1日 |
坂本 |
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial |
|
6月8日 |
Dr. Thang |
||
6月15日 |
夏目 |
Primary chemotherapy versus primary surgery for newly |
The Lancet, In Press, Corrected Proof, Available online 19 May 2015 |
6月22日 |
研修医1年 (吉津Dr) |
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell |
|
7月13日 |
深澤 T-MOC予演会 |
||
7月27日 |
研修医2年 (菊山Dr) |
Pembrolizumab for the Treatment |
|
8月3日 |
ASCO報告(市川) |
||
8月17日 |
ASCO報告(丹澤) |
||
8月24日 |
深澤 予演会 |
||
8月31日 |
研修医1年 (大野Dr) |
Pembrolizumab for the Treatment |
|
9月7日 |
渡邊 |
Obesity paradox in cancer: new insights provided by body |
|
9月14日 |
本田 |
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials |
|
9月28日 |
内科学会 地方会予演会 夏目 |
||
10月19日 |
太田 |
Use of thoracic radiotherapy for extensive stage small-cell |
|
10月26日 |
研修医1年 (西澤Dr) |
Effect of Duloxetine on Pain, Function, |
|
11月2日 |
深澤 |
Screening for Occult Cancer in Unprovoked Venous |
|
11月9日 |
市川 |
Impact of Specific Epidermal Growth Factor Receptor |
|
12月14日 |
丹澤 |
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. | Volume 90, Issue 3, December 2015, Pages 477–483 |
12月21日 |
渡邊 |
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer |
J Thorac Oncol. 2014;9: 1625–1633 |
12月28日 |
研修医1年 (熊木Dr) |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study | J Clin Oncol. 2015 Nov 10;33(32):3781-7. |
1月4日 |
深澤 |
Sensitivity and specifi city of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial |
Lanset.Volume 387, No. 10016, p341–348, 23 January 2016 |
1月25日 |
斉藤 |
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients | J Thorac Oncol. 2015;10: 1437–1443 |
2月1日 |
本田 |
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial |
The Lancet, Available online 21 December 2015, |
2月15日 |
市川 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial |
Lancet Oncol 2014; 15: 143–55 |
2月29日 |
研修医1年 |
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation |
N Engl J Med 2015;373:823-33. |
3月28日 |
丹澤 | First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. | J Thorac Oncol. 2016 Mar;11(3):380-90 |
2014年度 開催記録
日付 | 担当 | 論文タイトル | 掲載雑誌 |
4月28日 | 研修医(岩田) | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | JCO 2013 31(27) 3327-3334 |
5月12日 | 本田 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor AMeta-analysis |
JAMA. 2014;311(14):1430-1437. |
5月19日 | 森 | Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer | N Engl J Med 2014;370:1189-97. |
5月26日 | 丹澤 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial |
Lancet 2014; 383: 31–39 |
6月2日 | 深澤 | Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002 |
Jpn J Clin Oncol 2013;43(11)1115–1123 |
6月9日 | 太田 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial |
Lancet 2014; 383: 31–39 |
6月16日 | 坂本 | TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial |
Lancet Oncol 2012; 13: 993–1001 |
6月23日 | ASCO報告(市川) | ||
6月30日 | 研修医(酒井) | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial |
Lancet. 201423;384(9944):665-73 |
7月7日 | ASCO報告(市川) | ||
7月14日 | 臨床試験勉強会 | ||
7月28日 | 渡邊 | Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer | Ann Intern Med. 2014;161:20-30. |
8月11日 | 夏目 | Young childless women with breast cancer in the UK: a qualitative study of their fertility-related experiences, options, and the information given by health professionals |
Psycho-Oncology 23: 20–26 (2014) |
8月18日 | 本田 | Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data |
Lancet 2014; 383: 1561–71 |
8月25日 | 研修医(北川) | Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509 |
J Clin Oncol 32:1262-1268. 2014 |
9月1日 | 臨床試験勉強会 | ||
9月8日 | 森 | Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: U.S. Preventive Services Task Force Recommendation Statement |
Ann Intern Med. 2014;160:558-564. |
9月22日 | 太田 | Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial |
Lancet Oncol 2014; 15: 689–99 |
10月6日 | 深澤 | The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence |
Int. J. Mol. Sci. 2014, 15, 11832-11846 |
10月20日 | 丹澤 | Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia |
Intensive Care Med (2010) 36:612–620 |
10月27日 | 研修医 | Efficacy and safety of maintenance pemetrexed in patients withadvanced nonsquamous non-small cell lung cancer followingpemetrexed plus cisplatin induction treatment: A cross-trialcomparison of two phase III trials | Lung Cancer 85 (2014) 408–414 |
11月10日 | 坂本 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic diff erentiated thyroid cancer: a randomised, double-blind, phase 3 trial |
Lancet 2014; 384: 319–28 |
11月17日 | 渡邊 | New ultrasound techniques for lymph node evaluation | World J Gastroenterol 2013 August 14; 19(30): 4850-4860 |
12月1日 | 予演会 | ||
12月8日 | 夏目 | Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study |
Rev Psychiatr Neurosci 2005;30(2) |
12月15日 | 本田 | Possible differential EGFR-TKI efficacy among exon 19 deletionallocations in EGFR-mutant non-small cell lung cancer | Lung Cancer 86 (2014) 213–218 |
12月22日 | 研修医(森岡) | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-fi nding portion of a phase 1/2 study |
Lancet Oncol 2014; 15: 1119–28 |
1月19日 | 太田 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer |
N Engl J Med 2014;371:2167-77. |
1月26日 | 丹澤 | Frequency of brain metastases in non‑small‑cell lung cancer,and their association with epidermal growth factor receptor mutations | Int J Clin Oncol. 2014 Oct 22 |
2月9日 | 坂本 | Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan |
ANTICANCER RESEARCH 35: 371-378 (2015) |
2月16日 | 渡邊 | nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial |
JNCI J Natl Cancer Inst, 2015, 1–10 |
2月23日 | 丸山 | Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer |
N Engl J Med 2013;369:1023-34. |
3月9日 | 市川 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials |
Lancet Oncol 2015; 16: 141–51 |
3月16日 | 森 | Frequency of brain metastases in non‑small‑cell lung cancer, and their association with epidermal growth factor receptor mutations |
Int J Clin Oncol. 2014 Oct 22 |